Outcomes for Women with Gestational Diabetes Treated with Metformin: A Retrospective, Case-Control Study.

Outcomes for Women with Gestational Diabetes Treated with Metformin: A Retrospective, Case-Control Study.
Author Information (click to view)

McGrath RT, Glastras SJ, Scott ES, Hocking SL, Fulcher GR,


McGrath RT, Glastras SJ, Scott ES, Hocking SL, Fulcher GR, (click to view)

McGrath RT, Glastras SJ, Scott ES, Hocking SL, Fulcher GR,

Advertisement

Journal of clinical medicine 2018 03 097(3) pii E50
Abstract

Metformin is increasingly being used a therapeutic option for the management of gestational diabetes mellitus (GDM). The aim of this study was to compare the maternal characteristics and perinatal outcomes of women with GDM treated with metformin (with or without supplemental insulin) with those receiving other management approaches. A retrospective, case-control study was carried out and 83 women taking metformin were matched 1:1 with women receiving insulin or diet and lifestyle modification alone. Women managed with diet and lifestyle modification had a significantly lower fasting plasma glucose (< 0.001) and HbA1c (< 0.01) at diagnosis of GDM. Furthermore, women managed with metformin had a higher early pregnancy body mass index (BMI) compared to those receiving insulin or diet and lifestyle modification (< 0.001). There was no difference in mode of delivery, birth weight or incidence of large- or small-for-gestational-age neonates between groups. Women receiving glucose lowering therapies had a higher rate of neonatal hypoglycaemia (< 0.05). The incidence of other adverse perinatal outcomes was similar between groups. Despite their greater BMI, women with metformin-treated GDM did not have an increased risk of adverse perinatal outcomes. Metformin is a useful alternative to insulin in the management of GDM.

Submit a Comment

Your email address will not be published. Required fields are marked *

thirteen + 14 =